XLS Medical Appetite Reducer - Appetite Suppressant and Hunger Control for a more Efficient Weight Loss - 60 Capsules, 10 Days Treatment

£9.9
FREE Shipping

XLS Medical Appetite Reducer - Appetite Suppressant and Hunger Control for a more Efficient Weight Loss - 60 Capsules, 10 Days Treatment

XLS Medical Appetite Reducer - Appetite Suppressant and Hunger Control for a more Efficient Weight Loss - 60 Capsules, 10 Days Treatment

RRP: £99
Price: £9.9
£9.9 FREE Shipping

In stock

We accept the following payment methods

Description

Safety evaluation included measurement of laboratory parameters (full blood count, clinical chemistry, liver and renal functions and fat-soluble vitamins (A, D, E, and K) levels) and urine analysis at visit 1 and visit 6, as well as assessment of vital signs during each visit. Adverse events were recorded, regardless of causality at every visit. Global evaluation of tolerability by subjects and investigators was performed at the end of the study.

B. Grube, et al., “A Natural Fiber Complex Reduces Body Weight in the Overweight and Obese: A Double-Blind, Randomized, Placebo-Controlled Study,” Obesity 21, 58–64 (2013). Unfortunately, although obesity stems from consuming more calories than the body burns, more than 80% of overweight and obese individuals have trouble losing and maintaining weight loss through diet and exercise alone. These individuals recognise the serious health consequences of being overweight and often undertake drastic measures, including drug therapies and invasive surgeries, to achieve a healthier weight. Non-invasive weight management solutions Do not take Hunger Buddy during pregnancy or whilst breastfeeding, or if your BMI (Body Mass Index) is below 18.5. It is recommended that you calculate your BMI before and during use. Proprietary ingredient clinically shown to increase satiety and support significant weight loss in overweight and obese adults

Check store stock

For beneficial action of fibres on gastrointestinal transit, it is recommended to drink at least 2L of water a day. Slight constipation could occur in case of limited liquid intake. If constipation persists despite adequate fluid intake, please consult your healthcare professional. Direct comparisons of IQP-AE-103 with other weight loss agents that affect dietary fat absorption such as chitosan, Litramine®, or orlistat are difficult for methodological reasons. Ho et al. reported that there were no significant changes from baseline in body weight after 12 weeks of treatment with chitosan [ 39]. A treatment with Litramine® (a proprietary fibre complex) led to 3.8 kg weight loss after 12 weeks of intake [ 17]. As for orlistat (gastric and pancreatic lipase inhibitor), a study by Anderson et al. reported a 3.05 kg weight loss in overweight subjects after 16 weeks of treatment at 180 mg per day [ 40], whereas at higher dose of 360 mg per day, it caused a body weight reduction of 8.3 kg after 12-week period in obese women [ 41]. Our findings stand in line with results obtained by Wang et al., who demonstrated that okra intake decreased serum and hepatic total cholesterol and triglyceride levels, and enhanced fecal excretion of bile acids in mice [ 46]. In other study, Kahlon et al. showed that okra polysaccharides have strong bile acid binding properties [ 47]. Furthermore, Chen et al. reported that okra powder showed oil-binding capacities and cholesterol adsorption properties [ 48]. Additionally, results from animal study by Han et al. imply that inulin may also possess a fat-binding property besides its known beneficial effect as prebiotic, which contributed to a lower triglyceride and cholesterol levels in rats fed with high fat diet in the experiments [ 49]. Thus, the cholesterol-lowering effect of IQP-AE-103 could possibly be related to the physicochemical properties of both okra and inulin. The primary endpoint of this study was the comparison of the mean body weight (kg) change between IQP-AE-103 high dose and placebo after 12 weeks of intervention from baseline, in overweight and moderately obese subjects. The evaluation of the efficacy of IQP-AE-103 was based on the null hypothesis that there are no statistical differences between IQP-AE-103 and placebo in mean reduction of body weight after 12 weeks of treatment. The nonparametric Mann–Whitney U test for independent samples was applied. The testing was carried out by the determination of the rank sum of individual body weight changes. During the intervention period, no significant changes in fasting blood glucose and HbA1c levels were observed between the study groups. 67% of subjects in the IQP-AE-103 high-dose group had a reduction in triglyceride levels compared with 37% in the placebo group ( ). Changes in total/low-density lipoprotein (LDL)/high-density lipoprotein (HDL) cholesterol were not significant at the end of the study, but a post hoc subgroup analysis performed with subjects with baseline total cholesterol level above 6.2 mmol/L revealed pre-post reductions in total cholesterol of 1.22 ± 1.10 mmol/L ( ), 0.58 ± 0.90 mmol/L ( ), 0.13 ± 0.31 mmol/L ( ), and reductions in LDL cholesterol of 1.18 ± 1.06 mmol/L ( ), 0.49 ± 0.74 mmol/L ( ), and 0.23 ± 0.29 mmol/L ( ), in high-dose, low-dose IQP-AE-103, and placebo groups, respectively.

Objective. This study was performed to determine the efficacy and tolerability/safety of IQP-AE-103 on body weight reduction in overweight to moderately obese adults. Methods. A double-blind, randomized, placebo-controlled trial involved one hundred and eight subjects (BMI between 25 and 35 kg/m 2) that were randomly assigned to either the low-dose or the high-dose IQP-AE-103 group, or the placebo group. Following a 2-week run-in period, subjects received two capsules of investigational product after three daily main meals for 12 weeks. Subjects were instructed to maintain a nutritionally balanced hypocaloric diet according to the individual’s energy requirement. Body weight, body fat, and waist and hip circumference were measured at baseline, and after 2, 4, 8, and 12 weeks. Subjects also rated their feelings of hunger and fullness using visual analogue scales, and food craving on a 5-point scale at the same time intervals. Blood samplings for safety laboratory parameters were taken before and at the end of the study. Results. After 12 weeks of intake, the high-dose IQP-AE-103 group had a significantly greater weight loss compared with the placebo (5.03 ± 2.50 kg vs. 0.98 ± 2.06 kg, respectively; ) and the low-dose group (3.01 ± 2.19 kg; ). The high-dose group experienced a decrease in body fat of 3.15 ± 2.41 kg compared with a decrease of 0.23 ± 2.74 kg for the placebo group ( ). High-dose IQP-AE-103 also decreased the feeling of hunger in 66% subjects. A beneficial effect of IQP-AE-103 on the lipid metabolism was also demonstrated in the subgroup of subjects with baseline total cholesterol levels above 6.2 mmol/L. No side effects related to the intake of IQP-AE-103 were reported. Conclusions. These findings indicate that IQP-AE-103 could be an effective and safe weight loss intervention. This trial is registered with NCT03058367. 1. Introduction For all statistical analyses, the level of significance ( ) was assumed. Efficacy and safety data were analyzed based on full analysis set (FAS) population, which was defined as subjects who have received at least one dose of the investigational product and had a baseline and at least one postbaseline assessment. All statistical analyses were done using the SPSS statistic software, V22.0 (SPSS, Chicago, IL). Obesity is the fastest growing chronic disease — one that affects people of all ages. Its concomitant health risks are well documented, as is its role in the progression of other diseases, including cardiovascular disease, type 2 diabetes, respiratory problems and osteoarthritis. 1 U. Bongartz, et al., “Double-blind, Randomized, Placebo-Controlled, Bicentric Clinical Investigation to Evaluate the Benefit and Tolerability of Redusure IQP-AK-102 in Reducing Body Weight in Overweight and Obese Subjects,” Advancement in Medicinal Plant Research 4(3), 73–82 (2016). Current solutions include Litramine, which was awarded the first Class II medical device certification for a plant-based weight management product in the world, and Tanitol, the first enzyme inhibitor that achieved medical device certification by targeting multiple digestive enzymes.At the end of the study, significant reductions in mean BMI were seen in both high-dose (1.75 ± 0.83 kg/m 2, ) and low-dose (1.09 ± 0.75 kg/m 2, ) IQP-AE-103 subjects in comparison to the placebo group (0.34 ± 0.77 kg/m 2).

The mean reduction in waist circumference was more pronounced in both IQP-AE-103 groups, compared with that in the placebo group at the end of the study. Subjects in the high-dose IQP-AE-103 arm had a mean reduction in waist circumference of 4.1 ± 3.3 cm, whereas the mean reduction in the low-dose IQP-AE-103 arm was 2.5 ± 2.4 cm, in contrast to only 0.9 ± 1.6 cm reported in the placebo group ( and versus placebo, respectively). Also, there were statistically significant differences in the percentage of subjects with reduction in hip circumference between the study groups at week 12, between high-dose IQP-AE-103 and the placebo group (91.4% vs. 54.8%; ), as well as between low-dose IQP-AE-103 and placebo groups (80% vs. 54.8%; ), however, not between low- and high-dose IQP-AE-103 groups ( ). No statistically significant differences in waist-to-hip ratio between the study groups were reported at week 12. Based on the physicochemical properties of okra pods and inulin, and the fat binding capacity shown in vitro, it was hypothesized that a product containing powdered okra pods and inulin could potentially contribute to weight loss. Hence, the primary objective of this randomised, double-blind, placebo-controlled clinical study was to evaluate the weight loss potential of IQP-AE-103 over the period of 12 weeks in overweight and moderately obese subjects. In this study, it was demonstrated that in conjunction with a hypocaloric diet, IQP-AE-103 at both low dose (990 mg okra and 255 mg inulin/day) and high dose (1980 mg okra and 510 mg inulin/day) causes significant weight loss and that the effects are greater than those in the placebo. Baseline body weight was reduced by 5.03 ± 2.50 kg in the high-dose group and by 3.01 ± 2.19 kg in the low-dose group, compared with 0.98 ± 2.06 kg in the placebo group. Also, for the high-dose group, weight loss effect due to IQP-AE-103 consumption was observed as early as at 2 weeks of treatment and was sustained over the course of the 12-week intake period. More importantly, the proportion of subjects who lost at least 5% of baseline body weight was 60.0% in the high-dose IQP-AE-103 group, a proportion that is significantly higher than that in the low-dose and the placebo groups. Such weight loss due to the intake of IQP-AE-103 is considered to be of clinical relevance as European Medicines Agency associates a weight loss of 5% or more with a decrease of disease risk factors associated with overweight and obesity [ 38]. Subgroup analysis showed that although both IQP-AE-103 high- and low-dose consumptions led to significant weight loss in overweight subjects, for moderately obese subjects, only high dose caused a significant body weight reduction. Subgroup analysis also showed a statistically significant weight loss in both high- and low-dose IQP-AE-103 groups in subjects aged 41–65 years when compared with placebo group, whereas only the high-dose group showed a significant weight loss versus placebo in subjects aged 18–40 years. Weight management treatments range from natural, oral solutions to risky, invasive surgical procedures. In the dietary supplement industry, new products constantly offer promises to dieters; yet, most are born from similar technology and mechanisms of action. Blood lipid parameters, fasted glucose, and hemoglobin A1c (HbA1c) were assessed at visit 1 and visit 6. The animal and in vitro data used to support the findings of this study are currently under embargo, whereas the research findings are commercialized. Data requests will be considered by the corresponding author 12 months after publication of this article. Conflicts of Interest

FEATURES

All other efficacy as well as the safety and concurrent variables were exploratively examined and were descriptively assessed. For the metric data (continuous data), the statistical characteristics were given (number, mean, standard deviation, median, extremes, quartiles, and 95% confidence interval of mean). For ordinal data (discrete data), frequency distribution was performed. All nominal data (categorical data) were summarized using frequency tables. All variables were evaluated primarily by exact nonparametric procedures: (i) Kruskal–Wallis test for more than two independent groups (comparison of groups or subgroups) (ii) Mann–Whitney U test for independent groups (comparison of groups or subgroups) (iii) Wilcoxon test for dependent groups (comparison of pre-post within groups or subgroups) (iv) Fisher’s exact test for comparison of percentage. Each bmiSMART product complex has been tested for safety and efficacy, including placebo-controlled, randomised human clinical trials published in peer-reviewed, indexed journals. 3 A spectrum of weight management solutions Another finding of this study is that besides weight loss, IQP-AE-103 showed beneficial effects on lipid metabolism. A significantly higher proportion of subjects in the high-dose IQP-AE-103 group experienced a reduction in triglyceride levels at the end of the study compared with placebo. In subjects with higher baseline total cholesterol levels (>6.2 mmol/L), high dose of IQP-AE-103 was shown to significantly reduce total cholesterol and LDL-cholesterol (pre-post change). Therefore, current outcome suggests that long-term treatment with IQP-AE-103 could be beneficial for subjects with elevated blood lipid levels in reducing the risk of cardiovascular disease.



  • Fruugo ID: 258392218-563234582
  • EAN: 764486781913
  • Sold by: Fruugo

Delivery & Returns

Fruugo

Address: UK
All products: Visit Fruugo Shop